Wilson Therapeutics

scrapheap
Biotech

AZ licenses discarded rare disease drug to Monopar Therapeutics

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline, licensing Wilson disease candidate ALXN-1840.
Kevin Dunleavy Oct 24, 2024 2:54pm
Research development Image AstraZeneca

AstraZeneca hails late-phase win for Alexion rare disease drug

Aug 26, 2021 7:45am
Swedavia has sold a future Comfort hotel at Stockholm Arlanda Airport to boost the hotels competitive edge and meet growing

Alexion inks $855M takeover of Wilson Therapeutics

Apr 11, 2018 8:32am